• LAST PRICE
    2.8749
  • TODAY'S CHANGE (%)
    Trending Up0.0349 (1.2289%)
  • Bid / Lots
    2.8700/ 48
  • Ask / Lots
    2.8800/ 31
  • Open / Previous Close
    2.9000 / 2.8400
  • Day Range
    Low 2.8700
    High 2.9000
  • 52 Week Range
    Low 1.3300
    High 6.7200
  • Volume
    87,640
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 2.84
TimeVolumeABSI
09:32 ET221372.89
09:33 ET37422.885
09:35 ET86072.87
09:37 ET65082.875
09:39 ET6502.8775
09:42 ET4032.8797
09:44 ET27822.875
09:46 ET1002.8775
09:48 ET7042.8779
09:50 ET18042.875
09:51 ET8002.875
09:53 ET43002.8775
09:55 ET1002.8799
09:57 ET13002.87
10:00 ET59102.875
10:02 ET16832.875
10:04 ET19332.875
10:06 ET28432.875
10:08 ET1002.875
10:09 ET32872.8749
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesABSI
Absci Corp
322.5M
-3.1x
---
United StatesLYEL
Lyell Immunopharma Inc
323.5M
-1.4x
---
United StatesXOMA
XOMA Royalty Corp
353.6M
-9.8x
---
United StatesDSGN
Design Therapeutics Inc
328.4M
-6.6x
---
United StatesJSPR
Jasper Therapeutics Inc
308.6M
-4.1x
---
United StatesENGN
enGene Holdings Inc
337.4M
-1.7x
---
As of 2024-11-18

Company Information

Absci Corporation is a generative artificial intelligence (AI) drug creation company. The Company combines AI with scalable wet lab technologies to create biologics for patients. It has built an Integrated Drug Creation platform to identify novel drug targets, discover biotherapeutic candidates, and generate the cell lines to manufacture them in a single process. The Company uses its platform to predict, identify, design, construct, screen, select and scale production of biologic drug candidates for its partners, and learn from the data it generates. Its SoluPro technology is a multiplex synthetic biology approach that overcomes the limitations of highest-throughput automation labs. The Company supports its generative AI designs with its wet lab's high-throughput functional validation capabilities. It reconstructs prevalent immune-response molecules, such as antibodies from disease tissue and identify their corresponding antigens, offering new therapeutic targets.

Contact Information

Headquarters
18105 Se Mill Plain BlvdVANCOUVER, WA, United States 98683
Phone
360-949-1041
Fax
302-655-5049

Executives

Chief Executive Officer, Founder, Director
Sean Mcclain
Chief Financial Officer, Chief Business Officer, Treasurer, Director
Zachariah Jonasson
Independent Director
Andreas Busch
Lead Independent Director
Karen Mcginnis
Independent Director
Amrit Nagpal

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$322.5M
Revenue (TTM)
$4.2M
Shares Outstanding
113.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.12
EPS
$-0.94
Book Value
$1.89
P/E Ratio
-3.1x
Price/Sales (TTM)
76.7
Price/Cash Flow (TTM)
---
Operating Margin
-2,468.58%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.